NASDAQ:ADMA ADMA Biologics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ADMA Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.29 +0.11 (+5.05%) (As of 07/7/2022 10:15 AM ET) Add Compare Share Today's Range$2.14▼$2.3050-Day Range$1.43▼$2.2052-Week Range$1.01▼$2.32Volume39,710 shsAverage Volume3.53 million shsMarket Capitalization$448.66 millionP/E RatioN/ADividend YieldN/APrice Target$5.70 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ADMA Biologics MarketRank™ ForecastAnalyst RatingBuy3.20 Rating ScoreUpside/Downside147.8% Upside$5.70 Price TargetShort InterestBearish13.04% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.29) to ($0.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.51 out of 5 starsMedical Sector793rd out of 1,433 stocksBiological Products, Except Diagnostic Industry124th out of 220 stocks 3.6 Analyst's Opinion Consensus RatingADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.70, ADMA Biologics has a forecasted upside of 147.8% from its current price of $2.30.Amount of Analyst CoverageADMA Biologics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.04% of the outstanding shares of ADMA Biologics have been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in ADMA Biologics has recently increased by 0.95%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADMA. Previous Next 1.1 News and Social Media Coverage News SentimentADMA Biologics has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ADMA Biologics this week, compared to 1 article on an average week.Search InterestOnly 20 people have searched for ADMA on MarketBeat in the last 30 days. This is a decrease of -49% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions55.15% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ADMA Biologics are expected to grow in the coming year, from ($0.29) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address About ADMA Biologics (NASDAQ:ADMA) StockADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Read More ADMA Stock News HeadlinesJuly 6, 2022 | americanbankingnews.comHead to Head Comparison: ADMA Biologics (NASDAQ:ADMA) vs. Graphite Bio (NASDAQ:GRPH)June 27, 2022 | seekingalpha.comADMA's 6th plasma collection facility gets FDA approvalJuly 7, 2022 | Weekly Investor Alerts (Ad)A Bigger Opportunity For Growth…A smaller stock with a relatively low market cap often outperforms a larger company stock with a much higher market cap… And when an investor is spending fewer dollars for a stock purchase there’s a bigger opportunity for growth. Click Here for Our Top 5 Microcap Stocks. June 27, 2022 | markets.businessinsider.comWhy ADMA Biologics Shares Are Rising TodayJune 27, 2022 | finance.yahoo.comADMA BioCenters Receives FDA Approval for its Sixth Plasma Collection Center, Located in Myrtle Beach, SCJune 26, 2022 | finance.yahoo.comShareholders in ADMA Biologics (NASDAQ:ADMA) have lost 50%, as stock drops 12% this past weekJune 24, 2022 | americanbankingnews.comBrokerages Set ADMA Biologics, Inc. (NASDAQ:ADMA) Price Target at $5.70June 22, 2022 | uk.finance.yahoo.comADMA Biologics share price hits a one-year highJuly 7, 2022 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. June 16, 2022 | msn.com7ADMA : Looking Into ADMA Biologics's Return On Capital...May 12, 2022 | seekingalpha.comADMA Biologics: A Path To Profits Looks ClearMay 11, 2022 | benzinga.com2ADMA : Recap: ADMA Biologics Q1 EarningsMay 11, 2022 | seekingalpha.comADMA Biologics, Inc.'s (ADMA) CEO Adam Grossman on Q1 2022 Results - Earnings Call TranscriptMay 11, 2022 | finance.yahoo.comAdma Biologics (ADMA) Reports Q1 Loss, Tops Revenue EstimatesMay 11, 2022 | seekingalpha.comADMA Biologics up 4% after increasing 2022 revenue guidanceMay 11, 2022 | finance.yahoo.comADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business UpdateMay 11, 2022 | seekingalpha.comADMA Biologics Q1 2022 Earnings PreviewMay 10, 2022 | finance.yahoo.comWhat Kind Of Shareholders Own ADMA Biologics, Inc. (NASDAQ:ADMA)?May 4, 2022 | tmcnet.comADMA Biologics to Report First Quarter 2022 FinancialMay 4, 2022 | finance.yahoo.comADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022April 17, 2022 | finance.yahoo.comADMA Biologics, Inc. (NASDAQ:ADMA): When Will It Breakeven?March 25, 2022 | msn.comADMA Biologics' Q4 Top-Line Surpass Estimates, Concludes $175M Debt RefinancingMarch 25, 2022 | nasdaq.comADMA Biologics Says Its ASCENIV And BIVIGAM Get FDA Approval For Extended Shelf LifeMarch 25, 2022 | seekingalpha.comADMA Biologics gets FDA approval to extend shelf life of Asceniv, BivigamMarch 25, 2022 | finance.yahoo.comADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV™ & BIVIGAM® from 24 to 36 MonthsMarch 24, 2022 | seekingalpha.comADMA Biologics up in after-hours trading following quarterly top and bottom line beatsMarch 23, 2022 | markets.businessinsider.comHere's what Wall Street expects from ADMA Biologics's earningsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADMA CUSIPN/A CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees527Year FoundedN/ACompany Calendar Last Earnings5/11/2022Today7/07/2022Next Earnings (Estimated)8/10/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$5.70 High Stock Price Forecast$10.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+148.9%Consensus RatingBuy Rating Score (0-4)3.2 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,650,000.00 Net Margins-83.27% Pretax Margin-83.27% Return on Equity-59.36% Return on Assets-27.13% Debt Debt-to-Equity Ratio1.15 Current Ratio7.60 Quick Ratio3.19 Sales & Book Value Annual Sales$80.94 million Price / Sales5.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book3.18Miscellaneous Outstanding Shares195,920,000Free Float184,361,000Market Cap$448.66 million OptionableOptionable Beta1.03 ADMA Biologics Frequently Asked Questions Should I buy or sell ADMA Biologics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ADMA Biologics stock. View analyst ratings for ADMA Biologics or view top-rated stocks. What is ADMA Biologics' stock price forecast for 2022? 5 brokers have issued 12 month target prices for ADMA Biologics' shares. Their ADMA stock forecasts range from $3.00 to $10.00. On average, they anticipate ADMA Biologics' share price to reach $5.70 in the next twelve months. This suggests a possible upside of 161.5% from the stock's current price. View analysts' price targets for ADMA Biologics or view top-rated stocks among Wall Street analysts. How has ADMA Biologics' stock price performed in 2022? ADMA Biologics' stock was trading at $1.41 at the beginning of 2022. Since then, ADMA shares have increased by 54.6% and is now trading at $2.18. View the best growth stocks for 2022 here. When is ADMA Biologics' next earnings date? ADMA Biologics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for ADMA Biologics. How were ADMA Biologics' earnings last quarter? ADMA Biologics, Inc. (NASDAQ:ADMA) released its earnings results on Wednesday, May, 11th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.02. The biotechnology company had revenue of $29.10 million for the quarter, compared to analysts' expectations of $26.50 million. ADMA Biologics had a negative net margin of 83.27% and a negative trailing twelve-month return on equity of 59.36%. During the same period in the prior year, the business earned ($0.16) earnings per share. View ADMA Biologics' earnings history. What guidance has ADMA Biologics issued on next quarter's earnings? ADMA Biologics issued an update on its FY 2022 earnings guidance on Wednesday, June, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $130.00M-, compared to the consensus revenue estimate of $128.50 million. Who are ADMA Biologics' key executives? ADMA Biologics' management team includes the following people: Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 45, Pay $1.39M) (LinkedIn Profile)Dr. Jerrold B. Grossman D.P.S., Ph.D., Co-Founder & Vice Chairman (Age 74, Pay $70.9k)Mr. Brian Lenz CPA, CPA, Exec. VP, CFO & GM of ADMA BioCenters (Age 50, Pay $1.02M) (LinkedIn Profile)Ms. Kaitlin Kestenberg, VP of Compliance, Project Management & Clinical OperationsMr. Michael Goldstein, Sr. Director & Gen. CounselMr. Michael Least, VP of Sales & Commercial OperationsMr. Drew Pantello, VP of Marketing & Corp. Devel.Mr. Neal C. Fitzpatrick, VP of SalesDr. Gene A. Wetzstein BCOP, Pharm.D., Exec. Director & Head of Scientific EngagementMs. Cyndi Tolman, Sr. VP of Plasma Services What is Adam S. Grossman's approval rating as ADMA Biologics' CEO? 9 employees have rated ADMA Biologics CEO Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among ADMA Biologics' employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of ADMA Biologics' key competitors? Some companies that are related to ADMA Biologics include Allogene Therapeutics (ALLO), Recursion Pharmaceuticals (RXRX), Sana Biotechnology (SANA), Exscientia (EXAI), SpringWorks Therapeutics (SWTX), Adaptive Biotechnologies (ADPT), Vaxcyte (PCVX), Vericel (VCEL), Valneva (VALN), Kymera Therapeutics (KYMR), REGENXBIO (RGNX), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Replimune Group (REPL) and Alector (ALEC). View all of ADMA's competitors. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT). What is ADMA Biologics' stock symbol? ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA." How do I buy shares of ADMA Biologics? Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ADMA Biologics' stock price today? One share of ADMA stock can currently be purchased for approximately $2.18. How much money does ADMA Biologics make? ADMA Biologics (NASDAQ:ADMA) has a market capitalization of $427.11 million and generates $80.94 million in revenue each year. The biotechnology company earns $-71,650,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. How many employees does ADMA Biologics have? ADMA Biologics employs 527 workers across the globe. How can I contact ADMA Biologics? ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The official website for ADMA Biologics is www.admabiologics.com. The biotechnology company can be reached via phone at (201) 478-5552, via email at info@admabio.com, or via fax at 201-478-5553. This page (NASDAQ:ADMA) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
